Get the Stockscreener App
30.92
5.17%
1.52
Crinetics Pharmaceuticals Inc stock is traded at $30.92, with a volume of 1.36M.
It is up +5.17% in the last 24 hours and up +1.48% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$29.40
Open:
$29.79
24h Volume:
1.36M
Relative Volume:
1.69
Market Cap:
$2.91B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-8.2895
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
+0.65%
1M Performance:
+1.48%
6M Performance:
-17.46%
1Y Performance:
-41.92%
1-Day Range:
$29.63
$31.70
1-Week Range:
$28.73
$31.70
52-Week Range:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
30.92 | 2.80B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Crinetics Awaits FDA Approval Decision For Acromegaly Drug - RTTNews
Crinetics Pharmaceuticals Soars 21.42% on 150% Revenue Surge - AInvest
Published on: 2025-08-16 17:46:53 - metal.it
Published on: 2025-08-16 16:35:25 - 선데이타임즈
Crinetics Pharmaceuticals’ SWOT analysis: stock poised for growth as first drug nears approval - Investing.com Nigeria
Crinetics Pharmaceuticals Poised for Growth with PDUFA Approval Looming and Multiple Late-Stage Programs Underway - AInvest
Crinetics Pharma’s Earnings Call: Progress Amid Challenges - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2025 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Expands Team with 27 New Hires, Grants $2M+ in Equity Compensation Package - Stock Titan
Crinetics stock price target lowered to $86 by Citizens JMP on launch outlook - Investing.com Canada
Crinetics Pharmaceuticals Inc's Q2 2025 Earnings Call Highlights: Strategic Advancements, Financial Resilience Amid Rising Costs. - AInvest
Crinetics Pharmaceuticals' Q2 2025 Earnings: Financial Vulnerability and Clinical Dependencies Amid Pipeline Advancements - AInvest
Investors Might Be Losing Patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) Increasing Losses, as Stock Sheds 3.6% Over the Past Week - 富途牛牛
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Crinetics Pharmaceuticals: A Pipeline-Driven Inflection Point in Endocrine Therapeutics - AInvest
Crinetics 2025 Q2 Earnings Widening Losses Despite Revenue Surge - AInvest
How to read the order book for Crinetics Pharmaceuticals Inc.Free AI Trading Suggestions With Accuracy Focus - Newser
Transcript : Crinetics Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cadrenal Therapeutics shares rise 2.36% intraday after Crinetics Pharmaceuticals reported progress on PALSONIFY™ and Atumelnant development. - AInvest
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Stifel lowers Crinetics stock price target to $58 from $60, keeps Buy rating - Investing.com Canada
Earnings call transcript: Crinetics Pharmaceuticals Q2 2025 results miss EPS forecast - Investing.com
Crinetics Pharmaceuticals Inc. (CRNX) Shares Soar 11.91% on 150% Revenue Surge - AInvest
Crinetics Pharmaceuticals Q2 Earnings: Revenue Rises, Shares Up - AInvest
Crinetics Pharmaceuticals Q2 Loss Widens, Revenue Rises; Shares up Pre-Bell - MarketScreener
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Crinetics Pharmaceuticals Inc (CRNX) Q2 2025 Earnings Call Highlights: Strategic Advancements ... By GuruFocus - Investing.com Canada
Crinetics Pharmaceuticals Inc (CRNX) Q2 2025 Earnings Call Highl - GuruFocus
Will breakout in Crinetics Pharmaceuticals Inc. lead to full recoveryRisk Adjusted Trade Signal Screening Tool - Newser
Crinetics (CRNX) Q2 Revenue Jumps 150% - AOL.com
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics Pharmaceuticals: Promising Outlook with Anticipated Approval of Palsonify and Strategic Market Launch - TipRanks
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crinetics reports Q2 EPS ($1.23), consensus ($1.10) - TipRanks
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Risk Entry Zone Technical Analysis - Newser
Crinetics Pharma earnings missed by $0.13, revenue topped estimates - Investing.com Canada
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial - GuruFocus
Crinetics Q2: $1.2B cash, PDUFA date for PALSONIFY, atumelnant progress. - AInvest
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Crinetics Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Crinetics CRNX Q2 2025 Earnings Preview Downside Expected on Analyst EPS Downgrades - AInvest
Crinetics Pharmaceuticals, Inc. (CRNX)’ Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data - MSN
What are the technical indicators suggesting about Crinetics Pharmaceuticals Inc.Dynamic investment growth - Jammu Links News
Is it the right time to buy Crinetics Pharmaceuticals Inc. stockFastest-growing stock picks - Jammu Links News
What are analysts’ price targets for Crinetics Pharmaceuticals Inc. in the next 12 monthsStay informed with daily expert analysis - Jammu Links News
What institutional investors are buying Crinetics Pharmaceuticals Inc. stockFree Stock Movement Tracking - Jammu Links News
What is the risk reward ratio of investing in Crinetics Pharmaceuticals Inc. stockOver 200% growth - Jammu Links News
How strong is Crinetics Pharmaceuticals Inc. company’s balance sheetGet timely market insights for better trades - Jammu Links News
Real time alert setup for Crinetics Pharmaceuticals Inc. performanceConsistent Gain Plan with AI Support - Newser
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Aug 20 '25 |
Sale |
29.18 |
6,492 |
189,437 |
66,270 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):